Elanco Animal Health Inc's Chief Financial Officer, Robert M. VanHimbergen, recently reported the acquisition of 7.357 deferred stock units in a filing with the SEC. This transaction, dated November 13, 2026, is significant as it underscores the company’s approach to executive compensation and aligns the interests of its executives with those of shareholders.

Background

Elanco Animal Health Inc, classified under the SIC code 2834 for Pharmaceutical Preparations, operates as a prominent entity in the animal health sector. The company is publicly traded on the New York Stock Exchange under the ticker symbol ELAN. Elanco is known for its commitment to improving animal health through innovative solutions and products.

What the Filing Says

The recent SEC filing indicates that VanHimbergen acquired the deferred stock units at a price of $26.78 per share. Following this transaction, he now holds a total of 191.8191 shares. The filing states, "Each deferred stock unit represents the right to receive one share of Company common stock or the cash equivalent." This highlights the company’s strategy to incentivize executives with a focus on long-term performance.

Impact

This acquisition may affect various stakeholders, including shareholders and employees at Elanco. By aligning executive compensation with company performance, Elanco aims to enhance shareholder value and encourage a performance-driven culture within the organization.

What's Next

The filing does not say what happens next.